Skip to main content

Table 1 Baseline characteristics

From: Evaluation of myocardial involvement in patients with connective tissue disorders: a multi-parametric cardiovascular magnetic resonance study

 

All patients

SLEa

SSca

Other CTD

n = 40

n = 13

n = 17

n = 10

Age (yrs)

54 ± 17

45 ± 16

55 ± 16

62 ± 16

Gender (male)

5 (13 %)

3 (23 %)

1 (6 %)

1 (10 %)

Diagnosis

 Systemic lupus erythematosus

13 (33 %)

13 (100 %)

-

-

 Systemic sclerosis

17 (38 %)

-

17 (100 %)

-

 Overlap syndrome

6 (15 %)

-

-

6 (60 %)

 Sjögren’s syndrome

3 (7 %)

-

-

3 (30 %)

 Polymyositis

1 (2 %)

-

-

1 (10 %)

Cardiovascular risk factors

 Diabetes

1 (2 %)

-

-

1 (10 %)

 Hypertension

13 (33 %)

4 (33 %)

4 (23 %)

5 (50 %)

 Smokingb

14 (35 %)

6 (46 %)

7 (41 %)

1 (10 %)

 Hyperlipidemia

7 (18 %)

1 (8 %)

2 (12 %)

4 (40 %)

 Family history of CVD

14 (35 %)

6 (46 %)

4 (23 %)

4 (40 %)

 Obesity (BMI ≥ 30 kg/m2)

4 (10 %)

2 (15 %)

2 (12 %)

-

Symptoms (multiple possible)

 Angina

9 (23 %)

3 (23 %)

2 (12 %)

4 (40 %)

 Dyspnea

13 (33 %)

3 (23 %)

6 (35 %)

4 (40 %)

 Palpitations

3 (7 %)

1 (8 %)

-

2 (20 %)

 Syncope

1 (2 %)

-

-

1 (10 %)

 ECG abnormality

8 (20 %)

1 (8 %)

3 (18 %)

4 (40 %)

Years since diagnosis

  < 1

8 (20 %)

5 (38.5 %)

1 (6 %)

2 (20 %)

 1–4

12 (30 %)

2 (15 %)

9 (53 %)

1 (10 %)

 5–9

6 (15 %)

1 (8 %)

3 (18 %)

2 (20 %)

  ≥ 10

14 (35 %)

5 (38.5 %)

4 (23 %)

5 (50 %)

Disease activity

 SLEDAI

-

16 (6–23)

-

-

 ESSG

-

-

3.5 (1.4–5.5)

-

 Hematocrit

0.38 (0.34–0.40)

0.38 (0.34–0.40)

0.38 (0.34–0.42)

0.38 (0.37–0.39)

Medication

 Beta-blockers

6 (15 %)

4 (31 %)

-

2 (20 %)

 ARB

19 (48 %)

5 (39 %)

9 (53 %)

5 (50 %)

 ASA

6 (15 %)

1 (8 %)

2 (12 %)

3 (30 %)

 CCB

6 (15 %)

1 (8 %)

4 (23 %)

1 (10 %)

 Statins

7 (18 %)

3 (23 %)

2 (12 %)

2 (20 %)

 Diuretics

6 (15 %)

3 (23 %)

2 (12 %)

1 (10 %)

 Steroids

24 (60 %)

10 (77 %)

8 (47 %)

6 (60 %)

 NSAID

1 (2 %)

1 (8 %)

-

-

 Chloroquines

4 (10 %)

2 (15 %)

1 (6 %)

1 (10 %)

 Antibodies

1 (2 %)

1 (8 %)

-

-

 Cyclophosphamide

9 (23 %)

5 (39 %)

3 (18 %)

1 (10 %)

 Azathioprine

3 (8 %)

2 (15 %)

-

1 (10 %)

 Methotrexate

1 (2 %)

-

-

1 (10 %)

  1. All values are n (%) or mean ± SD or interquartile ranges
  2. SLE systemic lupus erythematosus, SSc systemic sclerosis, CTD connective tissue disease, CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, SLEDAI systemic lupus erythematosus disease activity index, ACR American College of Rheumatology, ESSG European scleroderma study group, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug
  3. apercentages based on number of SLE patients/SSc patients, respectively
  4. bCurrent or ever-smokers
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us